The International Headache Congress

IHS and EHF joint congress 2021
Headache science to optimise patient care
8–12 September 2021

Entrance to the virtual congress

Patient Course

IFHN

Company profiles


Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Teva has been treating CNS diseases for over thirty years, including migraine, multiple sclerosis (MS), Parkinson’s Disease (PD), Huntington’s Disease (HD) and Tardive Dyskinesia (TD). We are now among the first companies globally to launch a preventive treatment for migraine that has been featured in peer-reviewed publications and is now available to patients in many countries across the globe.


At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie's Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders, including Alzheimer's disease, bipolar disorder and depression, major depressive disorder, migraine, Parkinson's disease, spinal cord injuries, post-stroke spasticity, schizophrenia, stroke and others.  

We have a strong investment in neuroscience research, with our Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience Discovery site in Ludwigshafen, Germany, where our research and resilience in these challenging therapeutic areas is yielding a deeper understanding of the pathophysiology of neurological and psychiatric disorders, and identifying targets for potential disease-modifying therapeutics aimed at making a difference in people's lives. For more information, please visit www.abbvie.com


Novartis is a leading global medicines company that is reimagining medicine to improve and extend people’s lives, using innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. Find out more at www.novartis.com


Lundbeck is a global pharmaceutical company specialized in discovering and developing innovative treatments for brain diseases. At Lundbeck, we are tirelessly dedicated to restoring brain health.

Affiliated with the Ethical Committee for the Pharmaceutical Industry (enli.dk)

Governed by the Danish transparency reporting scheme under the Danish Medicines Agency. Registered with the Danish Association of the Pharmaceutical Industry (Lif).

Registered at the Danish Medicines Agency pursuant to section 7 and section 39 of the Medicines Act. Promotional activities are governed by The Danish Medicines Act (https://www.retsinformation.dk/eli/lta/2018/99) and the Executive Order on Advertising, etc. of medicinal Products (https://www.retsinformation.dk/eli/lta/2014/1153).

Please also refer to the website of the Danish Medicines Agency https://laegemiddelstyrelsen.dk/en/about/targets-and-tasks/legislation/the-danish-medicines-act/and the Danish Pharmaceutical Industry’s Code of Practice on Promotion of medicinal products aimed at Healthcare Professionals (https://www.enli.dk/media/49940/enli_ethical-rules-for-promotion-of-medicinal-products-towards-healthcare-professionals-uk-version-30-clean.pdf).

H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark;

VAT no: 56759913. 

Contact: info@lundbeck.com

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform therapy initially focused on the treatment of multiple conditions in neurology. The company’s first commercialized product, gammaCore™ (non-invasive vagus nerve stimulator) is the only hand-held medical therapy applied at the neck to provide treatment through the utilization of a safe and gentle electrical stimulation that passes through the skin to the vagus nerve. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain. gammaCore, is CE marked for the treatment and/or prevention of primary headache (migraine, cluster headache, and hemicrania continua) and medication overuse headache in adults. gammaCore is FDA-cleared for use in adult patients for adjunctive use for the preventive treatment of cluster headache, the acute treatment of pain associated with episodic cluster headache, and the acute and preventive treatment of migraine in adolescent (age 12 and older) and adult patients.